North Carolina Dermatologist. 2 full-time faculty positions at the level of Assistant or Associate Professor. Opportunities include: 1. Mohs Surgery - BE/BC Dermatologist with formal training in Mohs ...
Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform dermatologists and neurologists of a 2nd case of progressive multifocal leukoencephalopathy (PML) which resulted in the death of a 73-year old woman who had received RaptivaŽ (efalizumab) for approximately four years for treatment of chronic plaque psoriasis.
Cracking, chaffing, dry patches, and itchiness - all are unpleasant symptoms of dry and irritated skin that often comes with winter. As temperatures drop, the wind howls, and humidity levels hit an all-year low, our skin requires extra attention and care to stay healthy.
Bargains on consumer goods and services may be designed to encourage spending in tough economic times, however when related to cosmetic injections like Restylane, Juvederm or Botox, the multi-specialty Physicians Coalition for Injectable Safety warns that discounts raise a red flag.
According to a study published in the November issue of Archives of Dermatology, an effective treatment for plaque-type psoriasis can be found in traditional Chinese medicine. Yin-Ku Lin, M.D. (Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan) and colleagues found that an ointment based on the dark-blue, plant-based powder indigo naturalis can be used treat the skin condition.
A study published in the November issue of Archives of Dermatology seeks to determine which beachgoers would benefit from targeted interventions to reduce skin cancer risk by identifying sun-protection practices and risk profiles. In the past 30 years, the Unites States has seen a rapid increase in the incidence of skin cancer and death due to outdoor exposure to ultraviolet radiation (UVR).
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company and the U.S. Food and Drug Administration (FDA) have reached agreement on the design of a phase 3 registration trial for thymalfasin as a potential treatment for stage IV melanoma. Based on the FDA's review, the agency agrees that the design and planned analysis of SciClone's study adequately addresses the objectives necessary to support a regulatory submission.
Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform dermatologists and neurologists of a 2nd case of progressive multifocal leukoencephalopathy (PML) which resulted in the death of a 73-year old woman who had received RaptivaŽ (efalizumab) for approximately four years for treatment of chronic plaque psoriasis.
Cracking, chaffing, dry patches, and itchiness - all are unpleasant symptoms of dry and irritated skin that often comes with winter. As temperatures drop, the wind howls, and humidity levels hit an all-year low, our skin requires extra attention and care to stay healthy.
Bargains on consumer goods and services may be designed to encourage spending in tough economic times, however when related to cosmetic injections like Restylane, Juvederm or Botox, the multi-specialty Physicians Coalition for Injectable Safety warns that discounts raise a red flag.
According to a study published in the November issue of Archives of Dermatology, an effective treatment for plaque-type psoriasis can be found in traditional Chinese medicine. Yin-Ku Lin, M.D. (Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan) and colleagues found that an ointment based on the dark-blue, plant-based powder indigo naturalis can be used treat the skin condition.
A study published in the November issue of Archives of Dermatology seeks to determine which beachgoers would benefit from targeted interventions to reduce skin cancer risk by identifying sun-protection practices and risk profiles. In the past 30 years, the Unites States has seen a rapid increase in the incidence of skin cancer and death due to outdoor exposure to ultraviolet radiation (UVR).
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company and the U.S. Food and Drug Administration (FDA) have reached agreement on the design of a phase 3 registration trial for thymalfasin as a potential treatment for stage IV melanoma. Based on the FDA's review, the agency agrees that the design and planned analysis of SciClone's study adequately addresses the objectives necessary to support a regulatory submission.
